Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAILRussell Moser, Christopher J. Kemp, James Annis et al.|Cancer Research|2022Cited by 11
Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAILRussell Moser, Christopher J. Kemp, J. Annis et al.|Unknown|2023Cited by 0
Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAILRussell Moser, Christopher J. Kemp, J. Annis et al.|Unknown|2023Cited by 0
Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAILRussell Moser, Christopher J. Kemp, J. Annis et al.|Unknown|2023Cited by 0
Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAILRussell Moser, Christopher J. Kemp, J. Annis et al.|Unknown|2023Cited by 0